8 hours ago
1
Castle Biosciences (NASDAQ:CSTL) said on Wednesday that it has received breakthrough device designation from the U.S. Food and Drug Administration for its DecisionDx-Melanoma test.
The DecisionDx-Melanoma test analyzes gene expression profiles to test stage I-III cutaneous melanoma.
In another development, Revolution Medicines (
English (US) ·